argenx NV ADR (ARGX)vsInnoviva Inc (INVA)
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
INVA
Innoviva Inc
$20.66
+0.19%
HEALTHCARE · Cap: $1.53B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 1108% more annual revenue ($5.32B vs $440.00M). INVA leads profitability with a 81.2% profit margin vs 32.3%. INVA appears more attractively valued with a PEG of 0.26. INVA earns a higher WallStSmart Score of 85/100 (A-).
ARGX
Strong Buy73
out of 100
Grade: B
INVA
Exceptional Buy85
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Intrinsic value data unavailable for INVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 38 in profit
Keeps 81 of every $100 in revenue as profit
Strong operational efficiency at 43.3%
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : INVA
The strongest argument for INVA centers on PEG Ratio, P/E Ratio, Price/Book. Profitability is solid with margins at 81.2% and operating margin at 43.3%. Revenue growth of 19.3% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : INVA
The primary concerns for INVA are Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
INVA carries more volatility with a beta of 0.33 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INVA scores higher overall (85/100 vs 73/100), backed by strong 81.2% margins and 19.3% revenue growth. ARGX offers better value entry with a 64.8% margin of safety. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Innoviva Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?